Company: STAA
Filing Date: 2025-10-02
Form Type: DFAN14A
Source: 0001213900-25-095514
Chunk: 47

Company: STAAR SURGICAL CO
Filing Date: 2025-10-02
Form: DFAN14A
Chunk 47
---
 of opportunity, I think, in the refractive markets going forward.” David Endicott , Chief Executive Officer, Alcon Baird Healthcare Conference September 9, 2025 Alcon Can Accelerate the Adoption of STAAR’s EVO Platform Alcon Has Plenty of Dry Powder To Pay More On the acquisition side, we have the capability of doing a lot . I mean, the balance sheet's in a great place. And so, we could do something considerably larger.” David Endicott , Chief Executive Officer, Alcon Alcon Capital Markets Day March 27, 2025

CONFIDENTIAL © All rights reserved. Two Seas Capital LP INVESTOR PRESENTATION CONCLUSION 05

Broadwood Partners, L.P. Other Stockholders Have Publicly Criticized the Proposed Merger 67 [B] ased on our analysis, the proposed sale at the current proposed terms materially undervalues the Company and does not reflect the Company’s intrinsic value and its standalone prospects … We believe STAAR’s superior and proprietary technology, as well as its global scale, position the Company to take a significant portion of the fast - growing refractive surgery market, become an even more profitable enterprise and, ultimately, deliver upon its vision to be the first choice for surgeons and patients seeking visual freedom from glasses and contact lenses. In our view, there is no compelling reason to sell STAAR at this underwhelming price . Unless the terms are revised to address what we believe to be inadequate consideration, we intend to vote against the Proposed Merger …” 1 Christopher Min Fang Wang Chief Investment Officer Yunqi Capital Limited (owner of 5% of STAAR’s outstanding shares) 3 1. Source: Yunqi Capital Limited Press Release, September 22, 2025. 2. Source: Pascal Aeschlimann and David Bailey, “Alcon’s Bid for STAAR Surgical – A Commentary by Two Industry Executives,” LinkedI n, September 24, 2025. 3. Source: Yunqi Capital Limited Schedule 13D, filed with the SEC on September 22, 2025. “ Short - term operational issues have not been separated from the long - term asset value of STAAR. The undervalued stock price on which the accepted bid is based is the result of self - inflicted operational challenges. These should not be allowed to overshadow [STAAR’s] extremely positive structural growth drivers … Alcon’s current bid should have been viewed as a starting point by the STA